Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANQUILITY: BXCL501 in Agitation Associated With Dementia
NCT04251910Phase 2Completed
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Dec 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexmedetomidine in agitation (4 cohorts), sponsored by BioXcel Therapeutics, Inc. Primary endpoints: Positive and Negative Syndrome Scale-Excited Component Total Score at 2 hours and Adverse Events at 7 days. Started Dec 2019; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
agitation
Beyond the preview
Go deeper on NCT04251910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251910.